Abstract

Summary

This study investigates whether the effectiveness of light therapy for Seasonal Affective Disorder depends on illuminance (lux) or specific wavelengths, with particular attention to the role of melanopsin-containing ipRGCs. The findings suggest that wavelength composition matters for optimizing light therapy, as melanopsin's spectral sensitivity differs from classical photoreceptors, implying that blue-enriched light may be more effective at lower intensities.
Abstract

Key Findings

  • Melanopsin absorption spectrum in ipRGCs does not match that of classical photoreceptors, suggesting wavelength composition is a key variable in light therapy efficacy.
  • Blue-wavelength light is predicted to be a relatively better stimulator of melanopsin-containing ipRGCs compared to broad-spectrum white light at equivalent lux levels.
  • Findings imply that lux alone is insufficient as the sole parameter for standardizing SAD light therapy protocols; spectral quality must also be considered.
Categories

Categories

Seasonal Affective Disorder: Directly investigates light treatment parameters for SAD, comparing lux levels and wavelengths.
The Science of Light: Examines melanopsin and ipRGC spectral sensitivity in the context of therapeutic light exposure.
Authors

Author(s)

JL Anderson, CA Glod, J Dai, Y Cao
Publication Date

Publication Year

2009
Citations

Number of Citations

146
View more publications